# Study on Antiviral Therapy for HBeAg-positive Chronic Hepatitis B Patients Aged 1-16 Years

> **NCT04565262** · PHASE4 · UNKNOWN · sponsor: **Beijing 302 Hospital** · enrollment: 200 (estimated)

## Conditions studied

- HBeAg Positive Chronic Hepatitis B

## Interventions

- **DRUG:** NAs+IFN-α

## Key facts

- **NCT ID:** NCT04565262
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2023-07
- **Final completion:** 2023-09
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04565262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04565262, "Study on Antiviral Therapy for HBeAg-positive Chronic Hepatitis B Patients Aged 1-16 Years". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04565262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*